Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1617
    -0.0066 (-0.57%)
     

  • GBP/USD

    1.2373
    -0.0066 (-0.53%)
     

  • Bitcoin GBP

    52,055.02
    +1,224.59 (+2.41%)
     

  • CMC Crypto 200

    1,384.38
    +71.76 (+5.47%)
     

  • S&P 500

    4,972.25
    -38.87 (-0.78%)
     

  • DOW

    37,937.63
    +162.25 (+0.43%)
     

  • CRUDE OIL

    83.22
    +0.49 (+0.59%)
     

  • GOLD FUTURES

    2,410.20
    +12.20 (+0.51%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

UTHR vs. CORT: Which Stock Should Value Investors Buy Now?

Zacks Equity Research
·2-min read

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Corcept Therapeutics (CORT). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

Currently, United Therapeutics has a Zacks Rank of #2 (Buy), while Corcept Therapeutics has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that UTHR has an improving earnings outlook. But this is only part of the picture for value investors.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

ADVERTISEMENT

The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.

UTHR currently has a forward P/E ratio of 15.87, while CORT has a forward P/E of 28.12. We also note that UTHR has a PEG ratio of 1.76. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CORT currently has a PEG ratio of 2.50.

Another notable valuation metric for UTHR is its P/B ratio of 2.63. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, CORT has a P/B of 5.88.

These metrics, and several others, help UTHR earn a Value grade of B, while CORT has been given a Value grade of C.

UTHR sticks out from CORT in both our Zacks Rank and Style Scores models, so value investors will likely feel that UTHR is the better option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
United Therapeutics Corporation (UTHR) : Free Stock Analysis Report
 
Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research